Alain Jacquet1, Adeline Grolleau2, Jérémy Jove3, Régis Lassalle3, Nicholas Moore4. 1. Department of Clinical Pharmacology, University of Bordeaux Ségalen, Bordeaux, France docteur.alain.jacquet@wanadoo.fr. 2. Department of Clinical Pharmacology, University of Bordeaux Ségalen, Bordeaux, France INSERM CIC-P0005, Bordeaux, France. 3. INSERM CIC-P0005, Bordeaux, France ADERA, Pessac, France. 4. Department of Clinical Pharmacology, University of Bordeaux Ségalen, Bordeaux, France INSERM CIC-P0005, Bordeaux, France INSERM U657, Bordeaux, France.
Abstract
OBJECTIVE: To study the effect of a dietary supplement (TARGET 1®: a combination of casozepine, taurine, Eleutherococcus senticosus and extramel) on burnout symptomatology. METHODS: A 12-week, double-blind, randomized, placebo-controlled trial was conducted in workers engaged in professional contact with patients, students or clients. All were affected by burnout syndrome based on a score of ≥4 on the Burnout Measure Scale (BMS-10). The primary outcome measure was the change in the BMS-10 score; secondary outcome measures included the change in the Maslach's Burnout Inventory scale-Human Service Survey (MBI-HSS) score and the Beck Depression Inventory. Five scores were evaluated. RESULTS:Eighty-seven participants were enrolled in the study: 44 received the active formulation (verum group); 43 receivedplacebo. After 12 weeks' supplementation, the placebo group showed significant improvements in scores for BMS-10, MBI-HSS fatigue and the Beck Depression Inventory, but MBI-HSS depersonalization and task management were not improved; the verum group showed significant improvements in all five scores. The verum group consistently showed significantly greater improvements in scores than the placebo group. CONCLUSIONS: TARGET 1® significantly improved the symptoms of burnout after 12 weeks' use.
RCT Entities:
OBJECTIVE: To study the effect of a dietary supplement (TARGET 1®: a combination of casozepine, taurine, Eleutherococcus senticosus and extramel) on burnout symptomatology. METHODS: A 12-week, double-blind, randomized, placebo-controlled trial was conducted in workers engaged in professional contact with patients, students or clients. All were affected by burnout syndrome based on a score of ≥4 on the Burnout Measure Scale (BMS-10). The primary outcome measure was the change in the BMS-10 score; secondary outcome measures included the change in the Maslach's Burnout Inventory scale-Human Service Survey (MBI-HSS) score and the Beck Depression Inventory. Five scores were evaluated. RESULTS: Eighty-seven participants were enrolled in the study: 44 received the active formulation (verum group); 43 received placebo. After 12 weeks' supplementation, the placebo group showed significant improvements in scores for BMS-10, MBI-HSS fatigue and the Beck Depression Inventory, but MBI-HSS depersonalization and task management were not improved; the verum group showed significant improvements in all five scores. The verum group consistently showed significantly greater improvements in scores than the placebo group. CONCLUSIONS: TARGET 1® significantly improved the symptoms of burnout after 12 weeks' use.